PURPOSE: To evaluate the use of preoperative intravitreal bevacizumab (IVB) in patients undergoing parsplana vitrectomy (PPV) for complications of proliferative diabetic retinopathy (PDR). METHODS: We studied 22 patients with severe PDR. A preoperative complexity score (CS) was recorded. Eleven eyes were treated with IVB, 1.25 mg, 5-7 days before PPV (group 1), and 11 eyes underwent direct PPV (group 2). Surgical time and intra-operative manoeuvres were recorded. Main outcome measure was feasibility of surgery, secondary goal was the visual and anatomic outcome at 6 months. RESULTS: The average CS was 5.5, and was similar in the two groups. Mean surgical time was 57 minutes in group 1 vs 83 minutes in group 2; mean tool exchanges was 27 vs 53, intraoperative bleeding 5 vs 15, endodiathermy 2 vs 9. No complications were recorded after IVB. Meanpre-operative BCVA was 1.87 logMAR in group 1 and logMAR 2.04 in group 2. Meanpre-operative BCVA was 1.87 logMAR in the bevacizumab group and 2.04 logMAR in group 2, not significantly different (p = 0.7). Mean post-operative BCVA at 6 months was 0.88 logMAR in group 1 and logMAR 2.01 in control group 2, significantly different (p = 0.01). Post-operative BVCA improved in bevacizumab group from pre-operative value (p = 0.15), while in control group there was non-significant increase (p = 0.96). Anatomical attachment was achieved in 11 patients in group 1 vs nine patients in group 2. CONCLUSIONS: IVB administered prior to vitrectomy was well tolerated and reduced active neovascularization, thus facilitating PPV.
RCT Entities:
PURPOSE: To evaluate the use of preoperative intravitreal bevacizumab (IVB) in patients undergoing pars plana vitrectomy (PPV) for complications of proliferative diabetic retinopathy (PDR). METHODS: We studied 22 patients with severe PDR. A preoperative complexity score (CS) was recorded. Eleven eyes were treated with IVB, 1.25 mg, 5-7 days before PPV (group 1), and 11 eyes underwent direct PPV (group 2). Surgical time and intra-operative manoeuvres were recorded. Main outcome measure was feasibility of surgery, secondary goal was the visual and anatomic outcome at 6 months. RESULTS: The average CS was 5.5, and was similar in the two groups. Mean surgical time was 57 minutes in group 1 vs 83 minutes in group 2; mean tool exchanges was 27 vs 53, intraoperative bleeding 5 vs 15, endodiathermy 2 vs 9. No complications were recorded after IVB. Mean pre-operative BCVA was 1.87 logMAR in group 1 and logMAR 2.04 in group 2. Mean pre-operative BCVA was 1.87 logMAR in the bevacizumab group and 2.04 logMAR in group 2, not significantly different (p = 0.7). Mean post-operative BCVA at 6 months was 0.88 logMAR in group 1 and logMAR 2.01 in control group 2, significantly different (p = 0.01). Post-operative BVCA improved in bevacizumab group from pre-operative value (p = 0.15), while in control group there was non-significant increase (p = 0.96). Anatomical attachment was achieved in 11 patients in group 1 vs nine patients in group 2. CONCLUSIONS: IVB administered prior to vitrectomy was well tolerated and reduced active neovascularization, thus facilitating PPV.
Authors: Stephan Michels; Philip J Rosenfeld; Carmen A Puliafito; Erin N Marcus; Anna S Venkatraman Journal: Ophthalmology Date: 2005-06 Impact factor: 12.079
Authors: J Mordenti; R A Cuthbertson; N Ferrara; K Thomsen; L Berleau; V Licko; P C Allen; C R Valverde; Y G Meng; D T Fei; K M Fourre; A M Ryan Journal: Toxicol Pathol Date: 1999 Sep-Oct Impact factor: 1.902
Authors: John H Kempen; Benita J O'Colmain; M Cristina Leske; Steven M Haffner; Ronald Klein; Scot E Moss; Hugh R Taylor; Richard F Hamman Journal: Arch Ophthalmol Date: 2004-04
Authors: R A Grigorian; A Castellarin; R Fegan; C Seery; L V Del Priore; S Von Hagen; M A Zarbin Journal: Br J Ophthalmol Date: 2003-06 Impact factor: 4.638
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park Journal: N Engl J Med Date: 1994-12-01 Impact factor: 91.245
Authors: Elliott H Sohn; Shikun He; Leo A Kim; Hani Salehi-Had; Michael Javaheri; Christine Spee; Laurie Dustin; David R Hinton; Dean Eliott Journal: Arch Ophthalmol Date: 2012-09